This is the authors' abstract. We don't add key points for this paper.
Inflammatory bowel disease (IBD) presents unique clinical considerations related to fertility, medical therapy, and delivery planning. The strongest predictor of adverse pregnancy outcomes is active disease, making maintenance of remission a central management priority. Prepregnancy counseling for patients with IBD should address reproductive goals, nutritional status, and the potential effect of prior pelvic surgery on fertility. Most established IBD therapies, including aminosalicylates, thiopurines, and biologic agents, can be continued to maintain remission, whereas methotrexate is contraindicated, and Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators are generally avoided. Delivery planning should be individualized, with cesarean delivery generally favored for active perianal Crohn disease or rectovaginal fistula and shared decision making emphasized for patients with an ileal pouch–anal anastomosis. Optimal outcomes depend on coordinated multidisciplinary care that prioritizes disease control, treatment continuation, and individualized reproductive and delivery planning.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Boyd et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: